Brief: Ascletis Pharma Says Ind Filing Of Oral 3Clpro Inhibitor Asc11 Accepted By China Nmpa
29/11/2022 01:30
Nov 29 (Reuters) - Ascletis Pharma Inc 1672.HK :
* IND FILING OF ORAL 3CLPRO INHIBITOR ASC11 FOR COVID-19
ACCEPTED
BY CHINA NMPA
Source text for Eikon: ID:
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026